Proactiveinvestors recommends

Additional Information

Market:	ASX
Sector:	Pharma & Biotech
EPIC:	PRR
Latest Price:	0.17 (3.13% )
52-week High:	0.40
52-week Low:	0.15
Market Cap:	166.56M

1 year chart

1 day chart

Prima BioMed

Prima BioMed (ASX: PRR) is an Australian biotechnology company with a portfolio of products focussed in the therapeutic area of cancer. The current portfolio is the result of its affiliation with the Burnet Institute in Melbourne, a leading medical research institute with a focus in developing therapeutics for infectious diseases, cancer immunotherapies and autoimmune diseases.

Prima BioMed research program to develop oral delivery system for cervical cancer vaccine

Wednesday, November 18, 2009

Melbourne-based health care company Prima BioMed Ltd (ASX: PRR) has moved out of a trading halt to announce it will undertake a research program to develop an oral delivery system for a cervical cancer vaccine.

The company has engaged The University of New South Wales (UNSW) and University of Queensland (UQ) to undertake the research program to develop a cost effective oral cervical cancer vaccine in tablet form.

The research program will be under the leadership of Professor Ian Frazer, who was the developer of the GardasilTM vaccine, marketed by major global pharmaceutical companies, CSL Limited (ASX: CSL) and Merck Sharpe & Dome, and Professor Neil Foster and his team at the Supercritical Fluids Department at the University of New South Wales.

The development of an oral delivery system for cervical cancer vaccines will provide an alternative to an injection, which is currently the prime method of delivery for cervical cancer treatment.

Prima BioMed executive director Martin Rogers said: “A fully developed oral drug delivery platform would provide significant benefits to patients in the form of reduced side-effects, more efficient utilisation of dosages and improved patient compliance.”

A more effective means of administering cervical cancer vaccines represents an opportunity for Prima to significantly increase the level of inoculation for cervical cancer worldwide. This may have significant benefit for mass inoculation environments such as third world countries.

Prima’s plan is for the research program to lead to the development of a widely available, cost effective oral cervical cancer vaccine in tablet form to deliver cervical cancer vaccines.

The company the program would be of major importance to major pharmaceutical companies, searching for less invasive drug delivery systems and the desire to achieve increased drug bioavailability.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.